CytRx has announced the preliminary results from its Phase II trial of bafetinib, used to treat patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.
Sixteen patients were enrolled on the trial, who demonstrated greater-than or equal to 50% elevation in their lymphocyte counts, greater than 50% shrinkage in their lymph nodes. Lymph node softening was also noted.
The drug-related adverse effects sobserved were elevated liver enzymes with normal bilirubin, fatigue and gastrointestinal symptoms.
CytRx president and CEO Steven Kriegsman said that due to the low incidence of adverse events, the dose of bafetinib can be increased, thus increasing the potential for greater efficacy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData